9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



Trial Of Pembrolizumab And Nintedanib

Estimated reading time: < 1 min


Patients With Any Advanced Solid Tumors.

Estimated Enrollment: 18

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 2015-004511-21|2015/2329

Study First Received: August 2, 2016

Last Updated: August 4, 2016

Estimated Primary Completion Date: July 2021

Primary Outcome Measures:

MTD of Nintedanib

Sponsors and Collaborators:

Gustave Roussy, Cancer Campus, Grand Paris

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02856425

Was this article helpful?
Views: 81